• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Imprimis touts ‘dropless therapy’ study for cataract surgery

October 25, 2016 By Sarah Faulkner

Imprimis touts 'dropless therapy' study for cataract surgeryImprimis Pharmaceuticals (NSDQ:IMMY) touted data today from a peer-reviewed study of patients who received its “dropless therapy” following cataract surgery.

The San Diego-based company uses a compounded antibiotic and steroid formulation in single, injectable doses administered by physicians following ocular surgery. The treatment is designed to eliminate the need for patient-administered eye drops, potentially eliminating patient non-compliance or dosing errors. The compounded formulations use Imprimis’ patent-pending SSP technology, which helps active pharmaceutical ingredients solubilize into a well-distributed particle suspension.

The 922-patient study showed that in 92% of the cases, eye drops or supplemental medication were not needed after surgery if doctors gave patients the injectable, intraocular dropless therapy.

The paper will be published in January 2017 in Current Opinion in Ophthalmology. The authors reported that there were no major intra-operative complications associated with the injection, no cases of postoperative endophthalmitis, and that mean visual acuity was significantly increased at all postoperative visits, including the day after surgery. They also wrote that the rates of infection and inflammation appear similar to reported rates with alternative therapies like topical drops.

“I have performed over 5,000 cataract surgeries since Imprimis’ Tri-Moxi-Vanc was first introduced and, with the exception of steroid responsive and advanced glaucoma patients, I exclusively use TMV as a prophylactic alternative for my patients undergoing cataract surgery,” study author Dr. Sydney Tyson said in prepared remarks. ” As a result, I have had the opportunity to retrospectively compile and analyze the largest case series to date evaluating the clinical benefits of TMV. Although eye drops have been the current standard of care, there is a paradigm shift occurring as more surgeons are moving to single-use intraocular injections.”

Filed Under: Clinical Trials, Optical/Ophthalmic, Research & Development Tagged With: Imprimis Pharmaceuticals

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS